Dren Bio secures $350 million to advance blood-cancer therapy toward 2027 launch
read at Endpoints ↗DealPositive
Dren Bio, a California biotech firm, announced it has closed a financing round that raised $350 million.
The funding will be directed toward developing its lead blood‑cancer drug, with the company aiming to bring the product to market by the end of 2027.
Investors cited confidence in Dren Bio's platform and the potential to address unmet needs in hematologic cancers.
The sizable capital raise positions the company to accelerate late‑stage development amid a competitive biotech landscape.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Dren Bio raises $350M to get blood cancer drug onto market in 2027”
read at Endpoints ↗96 words · retrieved 44m ago
comments(0)
5-min edit window · permanent after that